It has previously been demonstrated in pancreatic cancer that miR-96 could suppress the expression of EVI1 via the binding with EVI1 3′UTR, and EVI1 could transcriptionally suppress the expression of miR-96 through binding with the EVI1 potential binding site around miR-96 (24). The gene discussed is MECOM; the disease is pancreatic neoplasm.